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In a recent issue ofNatureGenetics, Andersson and colleagues report thatMLL fusion alonemay be sufficient
to spawn an aggressive leukemia in infants. Some other pediatric cancers may share a similar, single, ‘‘big-
hit’’ origin, possibly reflecting a critical developmental window of stem cell vulnerability.Acute leukemias in infants are rare but
highly malignant and clinically intransi-
gent (Biondi et al., 2000). The majority of
leukemias have phenotypic features of
early or pro-B cells and recurrent rear-
rangements of MLL, predominantly as
chimeric gene fusions with AF4 (aka
AFF1) (Biondi et al., 2000).
Monozygotic twin infant pairs with
concordant acute lymphoblastic leuke-
mia (ALL) share an identical but non-
constitutive MLL genomic rearrangement
indicative of a single cell in utero origin
and progeny cell transfer via intra-
placental anastomoses (Greaves et al.,
2003). In non-twinned infants with ALL,
theMLL genomic sequence is detectable
in archived neonatal blood spots, sug-
gesting a pre-natal origin for most
patients (Gale et al., 1997). The concor-
dance rate for ALL in identical twin infants
with a monochorionic, or single placenta
is close to 100%. This, coupled with
the very short pre-clinical latency, has
suggested that MLL fusion might by
itself be sufficient for leukemia (Greaves
et al., 2003). Data from whole genome
sequencing of three cases of infant ALL
with MLL-AF4 fusion were compatible
with this notion (Dobbins et al., 2013). In
contrast, older children with B cell pre-cursor driven by ETV6-RUNX1 fusion or
hyperdiploidy also have a predominantly
in utero origin, but a requirement for addi-
tional post-natal mutations and a concor-
dance rate of 15% (Greaves et al.,
2003).
At face value, this possibility of a
single driver mutation conflicts with the
conventional notion that multiple and
sequential genetic changes need to be
accrued for a malignant phenotype to
emerge. In a recent publication, Ander-
sson et al. (2015) reported a detailed
genomic scrutiny of 22 cases of infant
ALL with MLLR (rearrangements). They
provided convincing evidence that MLL
gene fusion is the only detectable
genome-wide abnormality that is present
in all the cells. Other mutations are
present, particularly in the P13K-RAS
signaling pathway, but these are sub-
clonal (allele frequencies < 30%) and
not always retained in relapse. Older
children with MLL rearranged ALL had
more complex mutational landscapes.
These data suggest that, although
additional ‘‘driver’’ mutations occur
in infant ALL, the initiating lesion MLL
fusion is probably sufficient in itself to
spawn a large malignant clone (patients
with MLLR ALL have very high tumorburdens or white cell counts; Biondi
et al., 2000).
This important finding is not unique
to infant leukemia. In highly malignant
pediatric rhabdoid tumors, the only
discernible and recurrent exomic genetic
aberration is mutation and/or deletion,
leading to homozygous loss of function
in SMARCB1 (Lee et al., 2012). Paediatric
brain ependymomas subtypes are very
malignant but have remarkably silent
genomic landscapes with only one ge-
netic alteration: C11orf95-RELA fusion
found in most supratentorial ependymo-
mas (Parker et al., 2014). Other hindbrain
(posterior-fossa, group B) ependymomas
have no recurrent single nucleotide
variants, but large-scale copy number
changes (or aneuploidy) were present
along with genome-wide epigenetic
(methylation) changes (Mack et al.,
2014). It is possible that the sequencing
technologies employed in these studies
missed some cryptic mutational changes,
particularly in non-coding regions. Addi-
tionally, germline or constitutive genetic
variants may have contributed, epistat-
istically, to malignant transformation.
These caveats aside, the data collectively
argue that signal mutations can, excep-
tionally, have a major impact on cellularl 27, April 13, 2015 ª2015 Elsevier Inc. 433
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Previewsfitness and empower a fully
malignant phenotype.
Paediatric cancers gener-
ally have far fewer muta-
tions than adult epithelial
carcinomas (Vogelstein et al.,
2013), and it is possible that
two complementary driver
mutations could be sufficient,
in accord with Knudson’s
original two-hit hypothesis.
But how is it possible for a
single mutation to spawn a
fully-fledged malignant clone
and in such a short time
frame?
The answer may reside in
the functional properties of
the mutant genes that have
this capacity and theircontextual relation to the developmental
timing and cellular targets involved. It is
striking that all three genetic lesions
(MLL fusions, SMARCB1 deletion, and
C11orf95-RELA) corrupt regulation of
cell fate and gene transcription. MLL
proteins (and many of their fusion part-
ners) are global chromatin remodellers
(Krivtsov and Armstrong, 2007) as is
SMARCB1, as part of the SWI/SNF com-
plex (Lee et al., 2012). C11orf95-RELA
deregulates REL to activate multiple tran-
scriptional targets of canonial NF-kB
signaling (Parker et al., 2014).MLL fusions
have been reported to deregulate multiple
genes including CDKN1B (p27kip1), TERT
subunit of telomerase, TP53 and, in
particular, HOX genes. The latter are
normally downregulated in haemopoietic
differentiation but become fixed in an
‘‘on mode’’ in progenitor cells trans-
formed by MLLR, concomitant with the
expression of self-renewal or stem cell
signatures (Krivtsov and Armstrong,
2007). The pleiotypic impact of each of
the three mutant genes may have an
equivalent phenotypic impact on cellular
fitness as several independent mutations
in other genes.
Each of these three types of genetic ab-
normalities, or their signaling pathways, is
also found in adult cancers but in the
context of additional driver mutations.
There must therefore be something spe-
cial about the pediatric context or target
cells involved (Andersson et al., 2015;
Lee et al., 2012). The fitness impact of all
mutational drivers in cancer is contingent434 Cancer Cell 27, April 13, 2015 ª2015 Elsupon cell type, genotypic networks, and
epistasis in that cell type and local ecolog-
ical or micro-environmental conditions.
One plausible explanation for these
remarkable observations (Figure 1) is
that there is a developmental window dur-
ing embryonic or fetal development when
stem cells or progenitors are epigeneti-
cally plastic and in a very supportive or
permissive microenvironment for prolifer-
ative expansion. Mutation of cell-fate reg-
ulators at this critical stage might then
trap stem cells or progenitors in a self-re-
newing mode with no exit route of differ-
entiation available. A normally very active
but transitory cell expansion is now fixed
or stabilized. This proposition can be as-
sessed with modeling in murine systems
(Krivtsov and Armstrong, 2007; Parker
et al., 2014), though the relevant cell types
and tissue ecological context might be
tricky to access.
One prediction is that all cells experi-
mentally transformed by these particular
mutational changes will have constitutive
stem cell properties, in contrast to the
hierarchical lineage structure generated
in most cancers where fusion genes
and other initiating genetic lesions (e.g.,
ETV6-RUNX1 in childhood ALL) provide
a more subtle fitness advantage. There
is some evidence that MLL fusions are
potent stem cell converters (Krivtsov
and Armstrong, 2007; Somervaille and
Cleary, 2006). A corollary is that,
whereas most cancers follow a relatively
protracted and punctuated evolutionary
path, pediatric tumors of the typeevier Inc.described above have a
‘‘big bang’’ or explosive gen-
eration in a short time frame.
Having cells that can be
converted to highly malig-
nant derivatives by a single
step seems a very dangerous
liability. The fortunate rarity
of these cancers may then
reflect the very low probabil-
ity of those mutations occur-
ring during a very transient
time window and with only
small numbers of cells
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